Auto Summaries

Last updated: 2024 Nov 18

Total hit(s): 4416

S.No.
1	39112468	Structural basis for the interaction between human coronavirus HKU1 spike receptor binding domain and its receptor TMPRSS2.	N/A	Cell Discov	2024 Aug 8	4.65	1
2	38980748	Correction to: Modeling of host PDZ-dependent interactions with SARS-CoV-2 envelope protein and changes in PDZ protein expression in macrophages and dendritic cells.	N/A	J Leukoc Biol	2024 Jul 9	7.5	1
3	38824609	Correction: Conformational characterization of the mammalian-expressed SARS-CoV-2 recombinant receptor binding domain, a COVID-19 vaccine.	N/A	Biol Res	2024 Jun 1		1
4	38613382	Structural basis for polyuridine tract recognition by SARS-CoV-2 Nsp15.	N/A	Protein Cell	2024 Apr 13	5.52	1
5	38272241		N/A		2024 Apr		1
6	38438141	Wastewater-based epidemiological surveillance of SARS-CoV-2 new variants BA.2.86 and offspring JN.1 in south and Southeast Asia.	N/A	J Travel Med	2024 Mar 4	2.08	1
7	38522445	Increased faecal shedding in SARS-CoV-2 variants BA.2.86 and JN.1.	N/A	Lancet Infect Dis	2024 Mar 21	21.77	1
8	38426653	Corrigendum: Corrigendum: Binding of Glycans to the SARS CoV-2 Spike Protein, an Open Question: NMR Data on Binding Site Localization, Affinity, and Selectivity.	N/A	Chemistry	2024 Mar 12		1
9	38413411	Disruption of the blood-brain barrier is correlated with spike endocytosis by ACE2 + endothelia in the CNS microvasculature in fatal COVID-19. Scientific commentary on "Detection of blood-brain barrier disruption in brains of patients with COVID-19, but no evidence of brain penetration by SARS-CoV-2".	N/A	Acta Neuropathol	2024 Feb 27	18.14	1
10	38048665	Fixation and reversion of mutations in the receptor-binding domain of SARS-CoV-2 spike protein.	N/A	Diagn Microbiol Infect Dis	2024 Feb	2.33	1
11	38198216	Correction to: Dihydroisocoumarins of Hydrangea macrophylla var. thunbergii inhibit binding of the SARS-CoV-2 spike protein to ACE2.	N/A	Biosci Biotechnol Biochem	2024 Jan 10		1
12	37074202	Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults.	mRNA-1283 is a next-generation SARS-CoV-2 messenger RNA (mRNA)-based vaccine encoding two segments of the spike protein. At the interim analysis, no safety concerns were identified and no serious adverse events, adverse events of special interest, or deaths were reported.	Hum Vaccin Immunother	2023 Dec 31	4.7	1
13	36846890	Structure-based design of oligomeric receptor-binding domain (RBD) recombinant proteins as potent vaccine candidates against SARS-CoV-2.	The receptor-binding domain (RBD) of SARS-CoV-2 S protein is proved to be the major target of neutralizing antibodies. Only a portion of epitopes in RBD can be effectively displayed with dynamic changes in spatial conformations. Multimeric display of RBD molecules is a feasible strategy to optimize RBD-based vaccines.	Hum Vaccin Immunother	2023 Dec 31	4.7	1
14	36882925	A trimeric spike-based COVID-19 vaccine candidate induces broad neutralization against SARS-CoV-2 variants.	Emerging immune escape of SARS-CoV-2 variants pose great challenges to the development of vaccines based on original strains. Vaccine strategy of S-trimer protein formulated with CpG7909/aluminum hydroxide dual adjuvant may be considered a means to increase vaccine effectiveness against future variants.	Hum Vaccin Immunother	2023 Dec 31	4.7	1
15	36864628	Impaired antibody response to inactivated COVID-19 vaccines in hospitalized patients with type 2 diabetes.	Patients with type 2 diabetes (T2D) are at an increased risk of morbidity and mortality of coronavirus disease 2019 (COVID-19) T2D is associated with impaired antibody response to inactivated COVI-19 vaccine. The positive rate and median titer of IgG antibody against receptor-binding domain (anti-RBD) of spike (S) protein of SARS-CoV-2 were lower than in control group.	Hum Vaccin Immunother	2023 Dec 31	4.7	1
16	38097574	Long-COVID-19: the persisting imprint of SARS-CoV-2 infections on the innate immune system.	N/A	Signal Transduct Target Ther	2023 Dec 14	- n/a -	1
17	38097565	Host cyclophilin A facilitates SARS-CoV-2 infection by binding and stabilizing spike on virions.	N/A	Signal Transduct Target Ther	2023 Dec 14	- n/a -	1
18	36426608	Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses.	N/A	Emerg Microbes Infect	2023 Dec	5.84	1
19	37394992	Rational design of an influenza-COVID-19 chimeric protective vaccine with HA-stalk and S-RBD.	A two-in-one vaccine would be ideal to avoid multiple vaccinations for these diseases. The S-RBD from SARS-CoV-2 Delta was fused to the headless HA from H1N1 (H1Delta), creating a chimera that forms trimers in solution. Immunization with the vaccine elicited high and long-lasting neutralizing antibodies.	Emerg Microbes Infect	2023 Dec	5.84	1
20	36594480	COVID-19 vaccine hesitancy between family decision-makers and non-decision-makers among college teachers.	A cross-sectional online survey was administered across mainland China from 4 to 7 August 2021. Overall, 42.2% of the teachers were hesitant to being vaccinated against COVID-19. The hesitancy rate was lower among primary decision-makers than that among non-decision-makers. Those engaged in nursing education versus non-medical related professional education (OR = 2.67, 95% CI 1.29-5.49) were more likely to be hesitant.	Ann Med	2023 Dec	3.01	1
21	37359748	Seroprevalence of SARS-CoV-2 antibodies in dogs and cats during the early and mid-pandemic periods in Japan.	SARS-CoV-2 has continued to circulate in humans since its emergence in 2019. While infection in humans continues, numerous spillover events to at least 32 animal species, including companion and zoo animals, have been reported. Since dogs and cats are highly susceptible to the virus, it is important to know the prevalence of Sars-Cov-2 in these animals.	One Health	2023 Dec	3.81	1
22	37186902	Potential use of endemic human coronaviruses to stimulate immunity against pathogenic SARS-CoV-2 and its variants.	SARS-CoV-2 causes significant morbidity and mortality in humans. One factor that may influence virus control is pre-existing immunity conferred by an individual's past exposures to endemic coronaviruses (eCOVIDs) The nations where continuous exposures to eCOVIs are very high due to religious and traditional causes showed significantly lower cases and low mortality rates per 100,000.	Libyan J Med	2023 Dec	2.8	1
23	37114433	Mutations in SARS-CoV-2 variant nsp6 enhance type-I interferon antagonism.	A triple deletion (DeltaSGF or DeltaLSG) in nonstructural protein 6 augments nsp6-mediated antagonism of type-I interferon (IFN-I) signaling. The impact of mutations outside the Spike gene are poorly understood, but they may alter pathogenesis of SARS-CoV-2 variants in humans. Analyses of host responses from DeltaSGF-WA1-infected mice and primary airway cultures reveal activation of pathways indicative of a cytokine storm.	Emerg Microbes Infect	2023 Dec	5.84	1
24	37995658	Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.	N/A	Cell	2023 Nov 22	27.35	1
25	37813112	Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand.	N/A	Lancet Infect Dis	2023 Oct 6	21.77	1